Avid Bioservices Inc (CDMO)

[biopharm]

PS Targeting has been picking up much interest among researchers and scientists, seems to be all over the place recently and nice to see that Peregrine Pharmaceuticals has the patents for any and all targeting of flipped PS.

Here we have another research lab, this one in Japan and is the core reason why "Shigekazu Nagata" will be at the Keystone Symposium.

Nagata Lab

http://www2.mfour.med.kyoto-u.ac.jp/~nagata/english/members/members.html

------------------------------------

Nagata goes to Canada (2013)... for the Keystone Symposia

Nagata @Keystone Whistler Conference Center, Canada
March 26, 2013

17:00—19:00
Apoptosis and Necrosis

Shigekazu Nagata, Kyoto University, Japan
Exposure of Phosphatidylserine and Phosphatidylserine-Dependent Engulfment of Apoptotic Cells


http://www.keystonesymposia.org/14X8


-----------------------------------

Nagata goes to Brazil (2014)... for the Keystone Symposia

October 28—November 2, 2014
Casa Grande Hotel, Guaruja, São Paulo, Brazil

07:30—08:30
Breakfast

Individual Hotel
08:30—11:45
Consequences of Cell Death
Registered attendees can view abstracts starting on 09/28/2014

Imperial Ballroom
* Peter Vandenabeele, VIB, Ghent University, Belgium

Shigekazu Nagata, Kyoto University, Japan
Exposure of phosphatidylserine during apoptosis

http://www.keystonesymposia.org/index.cfm?e=web.Meeting.Program&meetingid=1321

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=105970876

----------------------------------------

Now why is this important? Why Shigekazu Nagata? Why is he continuing his PS Targeting research ? I believe its because he believes PS Targeting is the answer to many a question and what does he have to compare this to ?

Shigekazu Nagata is just about the king of "Interferon" research and does he believe Interferon is inferior to PS Targeting with Bavituximab ? I say absolutely yes!

So we have PS Targeting back on the table at the Keystone Symposia in March of 2014, we have Shigekazu Nagata studying "Interferon" during this career, yet he comes back to back at Keystone talking up PS Targeting? Sounds to me like the Japanese, as Joe Shan.... believes PS Targeting combo is a better alternative than an Interferon type combo.

--------------------------------------------------------

"We are pleased with the initial results we have seen from this clinical study evaluating the combination of bavituximab with an established antiviral drug in HCV patients. We see good evidence that the combination of bavituximab with ribavirin has a better safety profile than an interferon containing regimen which was one of the primary objectives of the study," said Joseph S. Shan, vice president of clinical and regulatory affairs at Peregrine Pharmaceuticals.

http://ir.peregrineinc.com/releasedetail.cfm?ReleaseID=636036

------------------------------------------------------